Tai Ling Pharmaceutical

Tai Ling Pharmaceutical is a pharmaceutical group focused on the R&D, manufacturing, and commercialization of therapeutic products in China, specializing in oncology, central nervous system (CNS) disorders, and respiratory diseases. The company is best known for its commercialization of Libod, a liposomal doxorubicin hydrochloride injection used in cancer treatment, and its acquisition of the rights to Seroquel (quetiapine) in Mainland China. Tai Ling operates an integrated business model that includes internal R&D centers and manufacturing facilities in Suzhou and Taizhou. The company has historically leveraged strategic acquisitions and licensing agreements with global firms like AstraZeneca to expand its portfolio in the Chinese market.